Helicobacter pylori seroprevalence in Crohn's disease: Lack of influence by pharmacological treatment

Mario Guslandi, L. Fanti, P. A. Testoni

Research output: Contribution to journalArticlepeer-review


Background/Aims: Helicobacter pylori infection has a low prevalence in Crohn's disease, possibly because of sulphasalazine therapy. We investigated Helicobacter pylori seroprevalence in patients with Crohn's disease never treated with sulphasalazine in order to assess the possible role of antibiotic treatment. Methodology: Two groups of patients with Crohn's disease (group I: subjects treated with ciprofloxacin, metronidazole or both during the last six months; Group II: subjects who were not given antibiotics during the last six months) and a control group of 30 patients with irritable bowel syndrome were considered. IgG anti-H. pylori levels were measured in all patients. Results: Serology was positive respectively in 16.6%, 13.3% and 36.6% of cases in the three groups. Conclusions: Our findings confirm the Helicobacter pylori infection is infrequent in Crohn's disease. Neither sulphasalazine nor antibiotics appear to play a role.

Original languageEnglish
Pages (from-to)1296-1297
Number of pages2
Issue number47
Publication statusPublished - 2002


  • Ciprofloxacin
  • Crohn's disease
  • Helicobacter pylori
  • Metronidazole
  • Sulphasalazine

ASJC Scopus subject areas

  • Gastroenterology


Dive into the research topics of 'Helicobacter pylori seroprevalence in Crohn's disease: Lack of influence by pharmacological treatment'. Together they form a unique fingerprint.

Cite this